Erica Denhoff / Icon Sportswire via Getty Images Boston Scientific shares ... of its cardiovascular products to $2.73 billion. The MedSurg division, which includes endoscopy, urology, and ...

Endoscopy (7.8 ... to gain momentum driven by our product pipeline, clinical evidence and commercial execution that position us well for the long term.” Boston Scientific increased its full ...

Endoscopy net sales were $678 ... chairman and CEO of Boston Scientific. "We continue to gain momentum driven by our product pipeline, clinical evidence and commercial execution that position ...

The company should continue to benefit from market share gains for some of its products, including Watchman. Our interactive dashboard analysis of the Boston Scientific’s FY 2024Q3 Earnings ...

Boston Scientific reported 29.2% growth for cardiology products and 11.8% growth in ... Urology (10.3%) and Endoscopy (7.8%) followed. Outlook: Boston Scientific forecasts net sales growth for ...

but investors pulled back due to a "pause" in a trial of key product in development. Boston Scientific's (NYSE: BSX) stock was down just over 1% as of 3:30, after it fell as far as 4% earlier in ...

Credit: Sundry Photography via Shutterstock. Boston Scientific has resumed enrolment for its AVANT GUARD clinical trial, after it was paused in October 2024to “assess a few unanticipated observations” ...

Boston Scientific is keeping the ball rolling in ... as well as 10.3% growth among medical surgical tools—including endoscopy, urology and neuromodulation—that totaled $1.479 billion.

Endoscopy Sales ... company is expanding its product portfolio with the anticipated acquisition of Exonics and the recent acquisition of Silk Road Medical. Boston Scientific Corp (NYSE:BSX ...